Takeda Pharmaceutical Co. Ltd. seems to be upbeat about the prospects for its pioneering NEDD8-activating enzyme inhibitor pevonedistat (TAK-924) after presenting new Phase II data on its combination use in higher-risk myelodysplastic syndromes (HR-MDS).
Results from the Pevonedistat-2001 trial presented at the virtual American Society of Clinical Oncology (ASCO) and European Hematology Association annual meetings showed benefits in this subgroup of patients across endpoints including overall survival (OS), event-free survival (EFS), complete
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?